Biosynthetic pathway to neuromelanin and its aging process

Pigment Cell and Melanoma Research

Volumn 25, Issue 6, 2012, Pages 792-803

  Wakamatsu, Kazumasa ^a   Murase, Takaya ^a   Zucca, Fabio A ^b   Zecca, Luigi ^b   Ito, Shosuke ^a  

^a FUJITA HEALTH UNIVERSITY   (Japan)

^b CNR   (Italy)

Author keywords

4 amino 3 hydroxyphenylethylamine; Cysteine; Dopamine; Neuromelanin; Thiazole 2,4,5 tricarboxylic acid

Indexed keywords

BENZOTHIAZINE DERIVATIVE; BENZOTHIAZOLE; CYSTEINE; DOPAMINE; MONOPHENOL MONOOXYGENASE; NEUROMELANIN;

AGING; ARTICLE; BIOSYNTHESIS; ENZYME DEGRADATION; ENZYME METABOLISM; ENZYME STRUCTURE; HUMAN; NEUROTOXICITY; OXIDATION;

BIOSYNTHETIC PATHWAYS; CYSTEINE; DOPAMINE; HUMANS; MELANINS; TIME FACTORS;

EID: 84867918494     PISSN: 17551471     EISSN: 1755148X     Source Type: Journal    
DOI: 10.1111/pcmr.12014     Document Type: Article

References (83)

1. Aime, S., Fasano, M., Bergamasco, B., Lopiano, L., and Valente, G. (1994). Evidence for a glicidic-lipidic matrix in human neuromelanin, potentially responsible for the enhanced iron sequestering ability of substantia nigra. J. Neurochem. 62, 369-371.
2. Arriagada, C., Paris, I., Sanchez de las Matas, M.J. et al. (2004). On the neurotoxicity mechanism of leukoaminochrome o-semiquinone radical derived from dopamine oxidation: mitochondria damage, necrosis, and hydroxyl radical formation. Neurobiol. Dis. 16, 468-477.
3. Barden, H. (1975). Histochemical relationship and nature of neuromelanin. Aging 1, 79-117.
4. Ben-Shachar, D., Riederer, P., and Youdim, M.B. (1991). Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J. Neurochem. 57, 1609-1614.
5. Bogerts, B. (1981). A brainstem atlas of catecholaminergic neurons in man, using melanin as natural marker. J. Comp. Neurol. 197, 63-80.
6. Bush, W.D., Garguilo, J., Zucca, F.A., Albertini, A., Zecca, L., Edwards, G.S., Nemanich, R.J., and Simon, J.D. (2006). The surface oxidation potential of human neuromelanin reveals a spherical architecture with a pheomelanin core and a eumelanin surface. Proc. Natl. Acad. Sci. USA 103, 14785-14789.
7. Carstam, R., Brinck, C., Hindemith-Augustsson, A., Rorsman, H., and Rosengren, E. (1991). The neuromelanin of the human substantia nigra. Biochim. Biophys. Acta 1097, 152-160.
8. Cowen, D. (1986). The melanoneurons of the human cerebellum (nucleus pigmentosus cerebellaris) and homologues in the monkey. J. Neuropathol. Exp. Neurol. 45, 205-221.
9. + binds to neuromelanin. Science 231, 987-989.
10. Double, K., Zecca, L., Costi, P. et al. (2000). Structural characteristics of human substantia nigra neuromelanin and synthetic dopamine melanins. J. Neurochem. 75, 2583-2589.
11. Double, K., Maruyama, W., Naoi, M., Gerlach, M., and Riederer, P. (2011). Biological role of neuromelanin in the human brain and its importance in Parkinson's disease. In Melanins & Melanosomes. J., Borovansky and P.A., Riley, eds. (Weinheim: Wiley-VCH), pp. 225-246.
12. Dzierzega-Lecznar, A., Kurkiewicz, S., Stepien, K., Chodurek, E., Riederer, P., and Gerlach, M. (2006). Structural investigations of neuromelanin by pyrolysis-gas chromatography/mas spectrometry. J. Neural. Transm. 113, 729-734.
13. Enochs, W.S., Sarna, T., Zecca, L., Riley, P.A., and Swartz, H.M. (1994). The role of neuromelanin, binding of metal ions, and oxidative cytotoxicity in the pathogenesis of Parkinson's disease: a hypothesis. J. Neural. Transm. [P-D Section], 7, 83-100.
14. Fasano, M., Giraudo, S., Coha, S., Bergamasco, B., and Lopiano, L. (2003). Residual substrantia nigra neuromelanin in Parkinson's disease is cross-linked to α-synuclein. Neurochem. Int. 42, 603-606.
15. Fasano, M., Bergamasco, B., and Lopiano, L. (2006). Is neuromelanin changed in parkinson's disease? Investigations by magnetic spectroscopies. J. Neural. Transm. 113, 769-774.
16. Fedorow, H., Tribl, F., Halliday, G., Gerlach, M., Riederer, P., and Double, K.L. (2005). Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog. Neurobiol. 75, 109-124.
17. Fedorow, H., Pickford, R., Kettle, E., Cartwright, M., Halliday, G.M., Gerlach, M., Riederer, P., Garner, B., and Double, K.L. (2006). Investigation of the lipid component of neuromelanin. J. Neural. Transm. 113, 735-739.
18. Fornstedt, B., Rosengren, E., and Carlsson, A. (1986). Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacol. 25, 451-454.
19. Graham, D.G. (1979). On the origin and significance of neuromelanin. Arch. Pathol. Lab. Med. 103, 359-362.
20. Graham, D.G., Tiffany, S.M., Bell W.R. Jr, and Gutknecht, W.F. (1978). Autooxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cells in vitro. Mol. Pharmacol. 14, 644-653.
21. Greco, G., Panzella, L., Gentile, G., Errico, M.E., Carfagna, C., Napolitano, A., and d'Ischia, M. (2011). A melanin-inspired pro-oxidant system for dopa(mine) polymerization: mimicking the natural casing process. Chem. Commum. 47, 10308-10310.
22. Haavik, J. (1997). L-DOPA is a substrate for tyrosine hydroxylase. J. Neurochem. 69, 1720-1728.
23. Hastings, T.G. (1995). Enzymatic oxidation of dopamine: the role of prostaglandin H synthase. J. Neurochem. 64, 919-924.
24. Ikemoto, K., Nagatsu, I., Ito, S., King, R.A., Nishimura, A., and Nagatsu, T. (1998). Does tyrosinase exist in neuromelanin-pigmented neurons in the human substantia nigra? Neurosci. Lett. 253, 198-200.
25. d'Ischia, M., and Prota, G. (1997). Biosynthesis, structure, and function of neuromelanin and its relation to Parkinson's disease: a critical update. Pigment Cell Res. 10, 370-376.
26. Ito, S. (2006). Encapsulation of a reactive core in neuromelanin. Proc. Natl. Acad. Sci. USA 103, 14647-14648.
27. Ito, S., and Wakamatsu, K. (1998). Chemical degradation of melanins: application to identification of dopamine-melanin. Pigment Cell Res. 11, 120-126.
28. Ito, S., and Wakamatsu, K. (2003). Quantitative analysis of eumelanin and pheomelanin in humans, mice, and other animals: a comparative review. Pigment Cell Res. 16, 523-531.
29. Ito, S., and Wakamatsu, K. (2006). Chemistry of Melanins. In The Pigmentary System. Physiology and Pathophysiology, J.J., Nordlund, R.E., Boissy, V.J., Hearing, R.A., King, W.S., Oetting, and J.P., Ortonne, eds. 2nd edn. (Oxford, UK: Blackwell Publishing), pp. 282-310.
30. Ito, S., and Wakamatsu, K. (2008). Chemistry of mixed melanogenesis - Pivotal roles of dopaquinone. Photochem. Photobiol. 84, 582-592.
31. Ito, S., Fujita, K., Yoshioka, M., Sienko, D., and Nagatsu, T. (1986). Identification of 5-S- and 2-S-cysteinyldopamine and 5-S-glutathionyldopamine formed from dopamine by high-performance liquid chromatography with electrochemical detection. J. Chromatogr. 375, 134-140.
32. Ito, S., Nakanishi, Y., Valenzuela, R.K., Brilliant, M.H., Kolbe, L., and Wakamatsu, K. (2011). Usefulness of alkaline hydrogen peroxide oxidation to analyze eumelanin and pheomelanin in various tissue samples: application to chemical analysis of human hair melanins. Pigment Cell Melanoma Res. 24, 605-613.
33. Jones, R.S.G., Juorio, A.V., and Boulton, A.A. (1983). Changes in levels of dopamine and tyramin in the rat caudate nucleus following alterations of impulse flow in the nigrostriatal pathway. J. Neurochem. 40, 396-401.
34. Land, E.J., and Riley, P.A. (2000). Spontaneous redox reactions of dopaquinone and the balance between the eumelanic and phaeomelanic pathways. Pigment Cell Res. 13, 273-277.
35. Li, H., and Dryhurst, G. (1997). Irreversible inhibition of mitochondrial complex I by 7-(2-aminoethyl)-3, 4-dihydro-5-hydroxy-2H-1, 4-benzothiazine-3-carboxylic acid (DHBT-1): a putative nigral endotoxin of relevance to Parkinson's disease. J. Neurochem. 69, 1530-1541.
36. 14C] diquat in frogs and mice: accumulation in neuromelanin. Neurosci. Lett. 93, 1-6.
37. Mann, D.M., and Yates, P.O. (1974). Lipoprotein pigments-their relationship to ageing in the human nervous system. II. The melanin content of pigmented nerve cells. Brain 97, 489-498.
38. Marsden, C.D. (1961). Pigmentation in the nucleus substantiae nigrae of mammals. J. Anat., 95, 256-261.
39. Matsunaga, J., Sinha, D., Pannell, L., Santis, C., Solano, F., Wistow, G.J., and Hearing, V.J. (1999). Enzyme activity of macrophage migration inhibitory factor toward oxidized catecholamines. J. Biol. Chem. 274, 3268-3271.
40. Mattammal, M.B., Strong, R., Lakshmi, V.M., Chung, H.D., and Stephenson, A.H. (1995). Prostaglandin H synthetase-mediated metabolism of dopamine: implication for Parkinson's disease. J. Neurochem. 64, 1645-1654.
41. Muñoz, P., Paris, I., Sanders, L.H., Greenamyre, J.T., and Segura-Aguilar, J. (2012). Overexpression of VMAT-2 and DT-diaphorase protects substantia nigra-derived cells against aminochrome neurotoxicity. Biochim. Biophys. Acta 1822, 1125-1136.
42. Naoi, M., Maruyama, W., and Dostert, P. (1995). Dopamine-derived 6, 7-dihydroxy-1, 2, 3, 4-tetrahydroisoquinolines; oxidation and neurotoxicity. Prog. Brain Res. 106, 227-239.
43. Napolitano, A., Pezzella, A., and Prota, G. (1999). New reaction pathways of dopamine under oxidative stress conditions: nonenzymatic iron-assisted conversion to norepinephrine and the neurotoxins 6-hydroxydopamine and 6, 7-dihydroxytetrahydroisoquinoline. Chem. Res. Toxicol. 12, 1090-1097.
44. Napolitano, A., Manini, P., and d'Ischia, M. (2011). Oxidation chemistry of catecholamines and neuronal degeneration: an update. Curr. Med. Chem. 18, 1832-1845.
45. Odh, G., Carstam, R., Paulson, J., Wittbjer, A., Rosengren, E., and Rorsman, H. (1994). Neuromelanin of the human substantia nigra: a mixed-type melanin. J. Neurochem. 62, 2030-2036.
46. Offen, D., Ziv, I., Barzilai, A., Gorodin, S., Glater, E., Hochman, A., and Melamed, E. (1997). Dopamine-melanin induces apoptosis in PC12 cells; possible implications for the etiology of Parkinson's disease. Neurochem. Int. 31, 207-216.
47. Offen, D., Gorodin, S., Melamed, E., Hanania, J., and Malik, Z. (1999). Dopamine-melanin is actively phagocytized by PC12 cells and cerebellar granular cells: possible implications for the etiology of Parkinson's disease. Neurosci. Lett. 260, 101-104.
48. Okun, M.R. (1997). The role of peroxidase in neuromelanin synthesis: a review. Physiol. Chem. Phys. Med. NMR 29, 15-22.
49. Ozeki, H., Ito, S., Wakamatsu, K., and Thody, A.J. (1996). Spectrophotometric characterization of eumelanin and pheomelanin in hair. Pigment Cell Res. 9, 265-270.
50. Palumbo, A., d'Ischia, M., Misuraca, G., De Martino, L., and Prota, G. (1995). Iron- and peroxide-dependent conjugation of dopamine with cysteine: oxidation routes to the novel brain metabolite 5-S-cysteinyldopamine. Biochim. Biophys. Acta 1245, 255-261.
51. Rankin, L.D., Bodenmiller, D.M., Partridge, J.D., Nishino, S.F., Spain, J.C., and Spiro, S. (2008). Escherichia coli NsrR regulates a pathway for the oxidation of 3-nitrotyramine to 4-hydroxy-3-nitrophenylacetate. J. Bacteriol. 190, 6170-6177.
52. Rosengren, E., Linder-Eliasson, E., and Carlsson, A. (1985). Detection of 5-S-cysteinyldopamine in human brain. J. Neural. Transm. 63, 247-253.
53. Saper, C.B., and Petito, C.K. (1982). Correspondence of melanin-pigmented neurons in human brain with A1-A14 catecholamine cell groups. Brain 105, 87-101.
54. Segura-Aguilar, J., Metodiewa, D., and Baez, S. (2001). The possible role of one-electron reduction of aminochrome in the neurodegenerative process of the dopaminergic system. Neurotox. Res. 3, 157-165.
55. Shen, X.M., and Dryhurst, G. (2001). Influence of glutathione on the oxidation chemistry of 5-S-cysteinyldopamine: potentially neuroprotective reactions of relevance to Parkinson's disease. Tetrahedron 57, 393-405.
56. Shen, X.M., Zhang, F., and Dryhurst, G. (1997). Oxidation of dopamine in the presence of cysteine: characterization of new toxic products. Chem. Res. Toxicol. 10, 147-155.
57. Silkaitis, R.P., and Mosnaim, A.D. (1976). Pathways linking L-phenylalanine and 2-phenylethylamine with p-tyramine in rabbit brain. Brain Res. 114, 105-115.
58. Simon, J.D., and Peles, D.N. (2010). The red and the black. Acc. Chem. Res. 43, 1452-1460.
59. Smythies, J. (1996). On the function of neuromelanin. Proc. R. Soc. Land. B. 263, 487-489.
60. Spencer, J.P.E., Whiteman, M., Jenner, P., and Halliwell, B. (2002). 5-S-cysteinyl-conjugates of catecholamines induce cell damage, extensive DNA base modification and increases in caspase-3 activity in neurons. J. Neurochem. 81, 122-129.
61. Sulzer, D., and Zecca, L. (2000). Intraneuronal dopamine-quinone synthesis: a review. Neurotox. Res. 1, 181-195.
62. Sulzer, D., Bogulavsky, J., Larsen, K.E. et al. (2000). Neuromelanin biosynthesis is driven by excess cytosolic catecholamines not accumulated by synaptic vesicles. Proc. Natl. Acad. Sci. USA 97, 11869-11874.
63. Sulzer, D., Mosharov, E., Talloczy, Z., Zucca, F.A, Simon, J.D., and Zecca, L. (2008). Neuronal pigmented autophagic vacuoles: lipofuscin, neuromelanin, and ceroid as macroautophagic responses during aging and disease. J. Neurochem. 106, 24-36.
64. Van Woert, M.H., and Ambani, L.M. (1974). Biochemistry of neuromelanin. Adv. Neurol. 5, 215-223.
65. Vauzour, D., Ravaioli, G., Vafeiadou, K., Rodriguez-Mateos, A., Angeloni, C., and Spencer, J.P. (2008). Peroxynitrite induced formation of the neurotoxins 5-S-cysteinyl-dopamine and DHBT-1: implications for Parkinson's disease and protection by polyphenols. Arch. Biochem. Biophys. 476, 145-151.
66. Vauzour, D., Corona, G., and Spencer, J.P.E. (2010). Caffeic acid, tyrosol and p-coumaric acid are potent inhibitors of 5-S-cysteinyl-dopamine induced neurotoxicity. Arch. Biochem. Biophys. 501, 106-111.
67. Wakamatsu, K., Ito, S., and Nagatsu, T. (1991). Cysteinyldopamine is not incorporated into neuromelanin. Neurosci. Lett. 131, 57-60.
68. Wakamatsu, K., Ito, S., and Rees, J.L. (2002). The usefulness of 4-amino-3-hydroxyphenylalanine as a specific marker of pheomelanin. Pigment Cell Res. 15, 225-232.
69. Wakamatsu, K., Fujikawa, K., Zucca, L., Zecca, L., and Ito, S. (2003). The structure of neuromelanin as studied by chemical degradative methods. J. Neurochem. 86, 1015-1023.
70. Wakamatsu, K., Ohtara, K., and Ito, S. (2009). Chemical analysis of late stages of pheomelanogenesis: conversion of dihydrobenzothiazine to a benzothiazole structure. Pigment Cell Melanoma Res. 22, 474-486.
71. Wakamatsu, K., Nakanishi, Y., Miyazaki, N., Ludger, K., and Ito, S. (2012). UVA-induced degradation of melanins: Fission of indole moiety in eumelanin and conversion of benzothiazine to benzothiazole moiety in pheomelanin. Pigment Cell Melanoma Res. 25, 434-445.
72. Xu, Y., Freeman, W.M., Kumer, S.C., Vogt, B.A., and Vrana, K.E. (1997). Tyrosinase mRNA is expressed in human substantia nigra. Brain Res. Mol. Brain Res. 45, 159-162.
73. Zareba, M., Bober, A., Korytowski, W., Zecca, L., and Sarna, T. (1995). The effect of a synthetic neuromelanin on yield of free hydroxyl radicals generated in model systems. Biochim. Biophys. Acta 1271, 343-348.
74. Zarow, C., Lyness, S.A., Mortimer, J.A., and Chui, H.C. (2003). Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Arch. Neurol. 60, 337-341.
75. Zecca, L., Pietra, R., Goj, C., Mecacci, C., Radice, D., and Sabbioni, E. (1994). Iron and other metals in neuromelanin, substantia nigra and putamen of human brain. J. Neurochem. 62, 1097-1101.
76. Zecca, L., Shima, T., Stroppolo, A., Goj, C., Battistron, G.A., Gerbasi, R., Sarna, T., and Swartz, H.M. (1996). Interaction of neuromelanin and iron in substantia nigra and other areas of human brain. Neuroscience 73, 407-415.
77. Zecca, L., Costi, P., Mecacci, C., Ito, S., Terreni, M., and Sonnino, S. (2000). Interaction of human substantia nigra neuromelanin with lipids and peptides. J. Neurochem. 74, 1758-1765.
78. Zecca, L., Tampellini, D., Gerlach, M., Riederer, P., Fariello, R., and Sulzer, D. (2001). Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol. Pathol. 54, 414-418.
79. Zecca, L., Fariello, R., Riederer, P., Sulzer, D., Gatti, A., and Tampellini, D. (2002). The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett. 510, 216-220.
80. Zecca, L., Zucca, F.A., Wilms, H., and Sulzer, D. (2003). Neuromelanin of the substantia nigra: a neuronal black hole with protective and toxic characteristics. Trends in Neurosci. 26, 578-580.
81. Zecca, L., Casella, L., Albertini, A., Bellei, C., Zucca, F.A., Engelen, M., Zadlo, A., Szewczyk, G., Zareba, M., and Sarna, T. (2008a). Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. J. Neurochem. 106, 1866-1875.
82. Zecca, L., Bellei, C., Costi, P. et al. (2008b). New melanic pigments in the human brain that accumulate in aging and block environmental toxic metals. Proc. Natl. Acad. Sci. USA 105, 17567-17572.
83. Zhang, F., and Dryhurst, G. (1993). Oxidation chemistry of dopamine: possible insights into the age-dependent loss of dopaminergic nigrostriatal neurons. Bioorg. Chem. 21, 392-410.